AdvisorShares STAR Global Buy-Write ETF (VEGA) Stock Price

49.0611 ▼ -0.6239 (-1.26%)
Open: 49.60 Vol: 5.92K Day's range: 48.984 - 49.60 Dec 29, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
VEGA Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL NEUTRAL NEUTRAL SELL BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 49.58▼ 49.58▼ 49.58▼ 49.41▼ 49.67▼
MA10 49.60▼ 49.50▼ 49.50▼ 49.51▼ 49.36▼
MA20 49.55▼ 49.59▼ 49.59▼ 49.66▼ 48.83▲
MA50 49.26▲ 48.46▲ 48.24▲ 49.34▼ 46.17▲
MA100 46.53▲ 45.87▲ 45.77▲ 48.68▲ 44.22▲
MA200 44.46▲ 43.30▲ 42.98▲ 46.48▲ 40.30▲
  5 mins 30 mins Hourly Daily Weekly
MACD -0.061▼ -0.111▼ -0.124▼ -0.074▼ -0.108▼
RSI 51.309▲ 54.615▲ 55.598▲ 43.981▼ 58.458▲
STOCH 32.716     53.225     53.225     56.021     77.086    
WILL %R -96.296▼ -51.316     -51.316     -74.774     -54.122    
CCI -118.222▼ -3.185     -3.185     -121.455▼ 3.522    
Latest Filters Detected On VEGA
RSI $VEGA RSI(14) Crossed Below 50 Set Alert
MA $VEGA Price Crossed Below MA(50) Set Alert
MA $VEGA Price Crossed Below MA(26) Set Alert
MA $VEGA Price Crossed Below MA(7) Set Alert
AdvisorShares STAR Global Buy-Write ETF News
Hut 8 Energizes Vega Data Center
Monday, June 30, 2025 03:30 AM
MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), an energy infrastructure platform integrating power, digital infrastructure, and compute at scale ...
Opus Genetics Announces Positive Topline Results from Phase 3 VEGA-3 Trial of Phentolamine Ophthalmic Solution for Presbyopia
Thursday, June 26, 2025 04:00 AM
Opus Genetics, Inc. announced positive topline results from its VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for treating presbyopia, achieving its primary and key ...
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Thursday, June 26, 2025 03:55 AM
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related ...
VEGA historical stock data
date open high low close volume
29/12/25 49.60 49.60 48.984 49.0611 5,915
26/12/25 49.4501 49.73 49.4501 49.685 2,986
24/12/25 49.59 49.59 49.535 49.535 2,163
23/12/25 49.87 49.91 48.66 49.4646 8,223
22/12/25 49.30 49.35 49.1001 49.32 3,581
19/12/25 49.79 49.8789 49.67 49.8789 1,593
18/12/25 49.65 49.67 49.3881 49.3881 1,715
17/12/25 49.65 49.67 49.49 49.5744 6,649
16/12/25 49.40 49.43 48.93 49.38 6,000
15/12/25 49.88 49.88 49.52 49.78 7,694
Quote Details
52wk Low:39.10
52wk High:50.25
Vol:5.92K
Avg Vol(3m):73.4K
1Y Chng:+13.36%
1M Chng:+0.06%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 0.00